Elidel-Study: Elidel in Patients With Atopic Dermatitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Atopic dermatitis is a common disease. Emollients and Elidel have both shown to be effective to treat this disease. The research question is, whether the effective component (Elidel) is better than the emollient to improve the skin function.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age > 18 years
Atopic dermatitis on both lower arms at least 1% body surface area.
Atopic Dermatitis Severity Index (ADSI)-Score >= 6
Investigator Global Assessment (IGA)-Score >= 2
Systemic therapy with immunosuppressive drugs within the past 24 weeks